Enhancing the peripheral chemoreflex to protect the newborn against hypoxic injury – A translational study based on fetal sheep model of birth asphyxia

Description of the granted funding

Severe birth asphyxia is a major cause of newborn mortality and in survivors birth asphyxia can cause life-long consequences that can manifest as neurologic morbidities. Birth asphyxia implies a decrease in systemic oxygenation and accumulation of pCO2 in fetal circulation. Typically during labor birth asphyxia develops if reperfusion time between uterine contractions is inadequate or placental function is suboptimal. If the newborn suffers from birth asphyxia, therapeutic hypothermia is the treatment of choice. In this study, we propose a new treatment to minimize the asphyxia-related brain abnormalities and improve long-term neurologic outcome. We test whether acetazolamide medication when given to the asphyxiated newborn will improve outcome. Studies on rats and mice have shown that acetazolamide significantly improves tissue oxygenation and inhibits seizure activity. We use fetal sheep model to test, if this drug can prevent newborn short- and long-term neurologic problems.
Show more

Starting year

2021

End year

2023

Granted funding

Juha Räsänen
250 000 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

342826

Fields of science

Genetics, developmental biology, physiology

Research fields

Kehitysbiologia ja fysiologia

Identified topics

gynecology, pediatrics